TENBORON

Tenboron is a clinical stage biopharmaceutical company developing novel carriers for biologically targeted cancer radiotherapy called Boron Neutron Capture Therapy, BNCT. BNCT involves delivering boron-10 atoms selectively to cancer cells. When low energy neutron radiation is applied, the boron will react inside the cancer cells destroying them but sparing the surrounding healthy cells. Our proprietary boron carriers have been designed to deliver high amounts of boron to cancer cells maximizing the efficacy of BNCT. Our spearhead product, an antibody-boron conjugate TB0010 is currently in phase 1 clinical development for recurrent head and neck carcinomas... Tenboron was founded in 2010 and started operation in late 2011. The inspiration came from the successful BNCT trials conducted at the Helsinki University Central Hospital and the VTT nuclear reactor facility FiR-1. Despite the good outcomes, it became clear that the boron carrier used in those trials was far from optimal... All..

Also known as: Tenboron Ltd, Tenboron Oy

Primary location: Helsinki Finland